What are Tau aggregation inhibitor drugs?

Tau aggregation inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Tau protein). 0 are currently marketed, with 4 more in clinical development.

Tau aggregation inhibitor

0 marketed 3 in Phase 3 1 in Phase 2

This page covers all Tau aggregation inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tau protein, tau protein.

Targets

Tau protein · tau protein

Phase 3 pipeline (3)

TAU-284 · Tanabe Pharma Corporation · Neurology
Tau-284 is a tau aggregation inhibitor.
TRx0237 · TauRx Therapeutics Ltd · Neurology
TRx0237 is a tau aggregation inhibitor.
Experimental: ALZ-801 · Alzheon Inc. · Neurology
ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain.

Phase 2 pipeline (1)

ACI-7104.056 at Dose A · AC Immune SA · Neurology
ACI-7104.056 is a tau aggregation inhibitor.